ERADICATION OF HELICOBACTER-PYLORI IN PATIENTS WITH END-STAGE RENAL-DISEASE UNDER DIALYSIS TREATMENT

The efficacy and safety of combination therapy with amoxicillin, lanso prazole, and plaunotol for the eradication of Helicobacter pylori in p atients on dialysis were evaluated, The study subjects comprised 15 di alysis patients in whom H pylori had been found in the gastric mucosa, The patients were given 500 mg amoxicillin once a day for 3 weeks, 30 mg lansoprazole once a day for 8 weeks, and 80 mg plaunotol three tim es a day for 24 weeks. Endoscopy was performed on entry and at 4 and 2 4 weeks after cessation of amoxicillin. The concentrations of serum ga strin and gastric juice ammonia also were measured. Fourteen patients completed the treatment protocol, one having dropped out because of na usea and diarrhea. H pylori was eradicated in 11 of the 14 patients 4 weeks after the end of amoxicillin therapy (eradication rate, 78.6%), All but one patient was free of H pylori 24 weeks after the amoxicilli n was discontinued, Patients who became negative for H pylori had sign ificantly decreased serum gastrin and gastric juice ammonia concentrat ions. Our findings indicate that a combination of amoxicillin, lansopr azole, and plaunotol can be used to eradicate H pylori in patients on dialysis. (C) 1997 by the National Kidney Foundation, Inc.